Journals / Journal of Medicine and Palliative Care / 2026 / Volume: 7 Issue: 3

Clinical characteristics and outcomes of ischemic stroke in patients receiving non–vitamin K antagonist oral anticoagulants

Deniz Kamacı Şener(BURSA ŞEHİR HASTANESİ)0000-0003-3433-6859
Cemile Haki(Bursa City Hospital)0000-0002-9679-8007
Tuba Kalkan(Bursa City Hospital)0009-0004-0298-5568
Pages
—
Publication Date
2026-06-25
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Improving medication adherence and appropriate dosing may also play an important role in patient management.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Ischemic stroke may still occur despite the use of non–vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation.
📊
Key Findings & Data:Methods: This retrospective single-center study included 139 patients receiving NOAC therapy who presented with acute ischemic stroke.
💡
Conclusion & Impact:Improving medication adherence and appropriate dosing may also play an important role in patient management.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Cardioembolic stroke · non-vitamin K oral anticoagulants (NOACs) · recurrent stroke

Abstract

Aims: Ischemic stroke may still occur despite the use of non–vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation. Data regarding the clinical characteristics and outcomes of these patients remain limited. This study aimed to evaluate the clinical characteristics of patients presenting with acute ischemic stroke despite ongoing NOAC therapy and to identify predictors of poor functional outcome. Methods: This retrospective single-center study included 139 patients receiving NOAC therapy who presented with acute ischemic stroke. Demographic, clinical, and treatment-related data were analyzed. Functional outcome at 3 months was assessed using the modified Rankin Scale (mRS), and factors associated with poor outcome were evaluated using multivariate logistic regression analysis. Results: The mean age was 75.5±9.9 years, and 57.6% of patients were female. Most patients (74.8%) were managed with medical treatment alone, while mechanical thrombectomy was performed in 23.0% of patients. Intravenous thrombolysis was rarely used (0.7%). Favorable functional outcome (mRS 0-2) at 3 months was observed in 56.1% of patients. Mechanical thrombectomy was identified as an independent predictor of favorable functional outcome (OR: 0.064, 95% CI: 0.009-0.446, p=0.006). In contrast, higher baseline NIHSS score and CHA₂DS₂-VASc score were independently associated with poor outcome. No significant differences were observed in clinical outcomes according to NOACs type, medication adherence, or dosing appropriateness. Conclusion: Ischemic stroke may still occur in patients receiving NOAC therapy, and its management remains challenging. Mechanical thrombectomy appears to be a key determinant of functional outcome and should be considered in appropriately selected patients. Improving medication adherence and appropriate dosing may also play an important role in patient management.

🔖

Cite This Article

Şener, D. K., Haki, C., Kalkan, T., Kamışlı, S. (2026). Clinical characteristics and outcomes of ischemic stroke in patients receiving non–vitamin K antagonist oral anticoagulants. Journal of Medicine and Palliative Care, Volume: 7 Issue: 3. https://doi.org/10.47582/jompac.1919989

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (31)

  1. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142(6):1489-1498. doi:10.1378/chest.11-2888
  2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638
  3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022
  4. Members ATF, Camm AJ, Lip GY, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747. doi:10.1093/eurheartj/ehs253
  5. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0
  6. Pinto DJ, Smallheer JM, Cheney DL, et al. Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem. 2010;53(17):6243-6274. doi:10.1021/jm100146h
  7. Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014;2014(3):CD009893. doi:10.1002/14651858.CD009893.pub2
  8. Gomez-Outes A, Suárez-Gea ML, Perez-Cabeza A-I, et al. Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions. Expert Opin Pharmacother. 2022;23(17):1941-1955. doi:10.1080/14656566.2022.2149323
  9. Sawczyńska K, Włodarczyk E, Pawlicka A, et al. Acute ischaemic stroke in patients treated with direct oral anticoagulants: potential causes, clinical characteristics, and short-term outcomes. Stroke Res Treat. 2024;2024:2285722. doi:10.1155/2024/2285722
  10. Caso V, de Groot JR, Fernandez MS, et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart. 2023;109(3):178-185. doi:10.1136/heartjnl-2022-321114
  11. Rodríguez LAG, Martín-Pérez M, Vora P, et al. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open. 2019;9(9):e031341. doi:10.1136/bmjopen-2019-031341
  12. Basaran Ö, Dogan V, Beton O, et al. Suboptimal use of non-vitamin K antagonist oral anticoagulants: results from the RAMSES study. Medicine. 2016;95(35):e4672. doi:10.1097/MD.0000000000004672
  13. Johansen MC, De Vasconcellos HD, Gottesman RF. Understanding atrial cardiopathy: an under-recognized contributor to cardioembolic stroke. Curr Treat Options Neurol. 2019;21(7):32. doi:10.1007/s11940-019-0571-4
  14. Kamel H, Longstreth Jr W, Tirschwell DL, et al. The AtRial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019;14(2):207-214. doi:10.1177/1747493018799981
  15. Yaghi S, Mistry E, Liberman AL, et al. Anticoagulation type and early recurrence in cardioembolic stroke: the IAC study. Stroke. 2020;51(9): 2724-2732. doi:10.1161/STROKEAHA.120.028867
  16. Bang OY, Park K-M, Jeong DS. Occurrence of ischemic stroke in patients with atrial fibrillation receiving non-vitamin K oral anticoagulants: causes and prevention strategies. J Stroke. 2023;25(2):199-213. doi:10.5853/jos.2022.03552
  17. Can Y, Ucaroglu N. Evaluation of the demographic characteristics of patients who had an ischemic stroke while using non-vitamin K antagonist oral anticoagulant. J Human Rhythm. 2020;6(1):15-24.
  18. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272. doi:10.1378/chest.09-1584
  19. Sun Y, Ling Y, Chen Z, et al. Finding low CHA2DS2-VASc scores unreliable? Why not give morphological and hemodynamic methods a try? Front Cardiovasc Med. 2023;9:1032736. doi:10.3389/fcvm.2022.1032736
  20. Quinn GR, Severdija ON, Chang Y, et al. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation. 2017;135(3):208-219. doi:10.1161/CIRCULATIONAHA.116.024057
  21. Baran O, Yilmaz Y, Inci S, et al. Use of the CHA2 DS2 VASc score to predict concurrent critical coronary artery stenosis in patients with severe carotid artery disease. Niger J Clin Pract. 2025;28(4):487-495. doi:10.4103/njcp.njcp_759_24
  22. Tourountzis T, Lioulios G, Stasini F, et al. Cardiovascular events and mortality in patients on hemodialysis: the prognostic value of the CHA2DS2-VASc score. Medicina. 2024;60(1):144. doi:10.3390/medicina60010144
  23. Boncoraglio GB, Del Giovane C, Tramacere I. Antihypertensive drugs for secondary prevention after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2021;52(6):1974-1982. doi:10.1161/STROKEAHA.120.031945
  24. Akboga YE, Bektas H. The prognostic value of the CHA2DS2-VASc score for predicting in-hospital mortality and short-term outcomes in patients with acute ischemic stroke. Noro Psikiyatr Ars. 2025;63:9-15. doi:10.29399/npa.28900
  25. Szymanski FM, Lip GY, Filipiak KJ, et al. Stroke risk factors beyond the CHA2DS2-VASc score: can we improve our identification of “high stroke risk” patients with atrial fibrillation? Am J Cardiol. 2015;116(11):1781-1788. doi:10.1016/j.amjcard.2015.08.049
  26. Okşen D, Aslan M, Yavuz YE. Comparative prognostic value of CHA2DS2-VASc score and atherogenic plasma index for one-year mortality prediction in ischemic stroke patients. Bagcilar Med Bull. 2025;10(1):8-14. doi:10.4274/BMB.galenos.2025.57966
  27. Meinel TR, Wilson D, Gensicke H, et al. Intravenous thrombolysis in patients with ischemic stroke and recent ingestion of direct oral anticoagulants. JAMA Neurol. 2023;80(3):233-243. doi:10.1001/jamaneurol.2022.4782
  28. Kam W, Holmes DN, Hernandez AF, et al. Association of recent use of non–vitamin K antagonist oral anticoagulants with intracranial hemorrhage among patients with acute ischemic stroke treated with alteplase. JAMA. 2022;327(8):760-771. doi:10.1001/jama.2022.0948
  29. Alam K, Khan AN, Fatima A, et al. Assessing mortality and safety of IV thrombolysis in ischemic stroke patients on direct oral anticoagulants (DOACs): a systematic review and meta-analysis. Clin Neurol Neurosurg. 2024;246:108523. doi:10.1016/j.clineuro.2024.108523
  30. Chen J-H, Hong C-T, Chung C-C, et al. Safety and efficacy of endovascular thrombectomy in acute ischemic stroke treated with anticoagulants: a systematic review and meta-analysis. Thromb J. 2022; 20(1):35. doi:10.1186/s12959-022-00394-y
  31. Seiffge DJ, Hooff R-J, Nolte CH, et al. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation. 2015;132(13):1261-1269. doi:10.1161/CIRCULATIONAHA.115.015484